<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000641</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 135</org_study_id>
    <secondary_id>11110</secondary_id>
    <nct_id>NCT00000641</nct_id>
  </id_info>
  <brief_title>A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.</brief_title>
  <official_title>A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the effectiveness and toxicity of two combination drug treatment programs for the&#xD;
      treatment of disseminated Mycobacterium avium infection in HIV seropositive patients. [Per&#xD;
      03/06/92 amendment: to evaluate the efficacy of azithromycin when given in conjunction with&#xD;
      either ethambutol or clofazimine as maintenance therapy.] Disseminated M. avium infection is&#xD;
      the most common systemic bacterial infection complicating AIDS in the United States. The&#xD;
      prognosis of patients with disseminated M. avium is extremely poor, particularly when it&#xD;
      follows other opportunistic infections or is associated with anemia. Test tube studies and&#xD;
      clinical data indicate that the best treatment program may include clofazimine, ethambutol, a&#xD;
      rifamycin derivative, and ciprofloxacin. Test tube and animal studies indicate that amikacin&#xD;
      is a bactericidal (bacteria destroying) drug that works better when used with ciprofloxacin.&#xD;
      Its role in treatment programs is a key issue because of toxicity and because it must be&#xD;
      administered parenterally (by injection or intravenously).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disseminated M. avium infection is the most common systemic bacterial infection complicating&#xD;
      AIDS in the United States. The prognosis of patients with disseminated M. avium is extremely&#xD;
      poor, particularly when it follows other opportunistic infections or is associated with&#xD;
      anemia. Test tube studies and clinical data indicate that the best treatment program may&#xD;
      include clofazimine, ethambutol, a rifamycin derivative, and ciprofloxacin. Test tube and&#xD;
      animal studies indicate that amikacin is a bactericidal (bacteria destroying) drug that works&#xD;
      better when used with ciprofloxacin. Its role in treatment programs is a key issue because of&#xD;
      toxicity and because it must be administered parenterally (by injection or intravenously).&#xD;
&#xD;
      Patients undergo an initial 2-week observation period (days 1 - 14) during which time&#xD;
      baseline evaluations are performed and type and severity of symptoms are monitored. Eligible&#xD;
      patients are randomized on day 15 to one of two treatment programs: (1) ciprofloxacin,&#xD;
      clofazimine, ethambutol, and rifampin (all taken orally), or (2) the same four drugs plus&#xD;
      amikacin. Only patients for whom blood cultures obtained on either day 1 or day 14/15 are&#xD;
      positive by week 6 continue on study drugs. Patients receive combination therapy for 24&#xD;
      weeks. Patients may have an indwelling central venous catheter in place for long-term&#xD;
      administration of intravenous drug. PER 03/06/92 AMENDMENT: Newly enrolled patients who&#xD;
      demonstrate a complete or partial clinical response at the end of study week 10 (8 weeks of&#xD;
      drug therapy) discontinue their current regimen and begin maintenance therapy with&#xD;
      azithromycin plus either ethambutol or clofazimine for an additional 24 weeks. Patients who&#xD;
      do not demonstrate a response at study week 10 are discontinued from all study therapy.&#xD;
      Patients enrolled on earlier versions of the protocol who have surpassed study week 16 (14&#xD;
      weeks of drug therapy) continue treatment with their originally assigned regimen through&#xD;
      study week 26; those who have not surpassed study week 16 are considered for inclusion in the&#xD;
      maintenance phase of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">December 1994</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>90</enrollment>
  <condition>Mycobacterium Avium-intracellulare Infection</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amikacin sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Zidovudine (AZT) and didanosine (ddI). Dideoxycytidine (ddC), EPO, and other&#xD;
             experimental therapies granted Treatment IND or Expanded Access status, with the&#xD;
             exception of rifabutin.&#xD;
&#xD;
          -  Concurrent therapies (acute and maintenance) for opportunistic infections not&#xD;
             specifically prohibited.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Interferon-alfa.&#xD;
&#xD;
        Patients must have the following:&#xD;
&#xD;
          -  HIV infections or diagnosis of AIDS as per CDC classification.&#xD;
&#xD;
          -  Mycobacterium avium isolated from blood.&#xD;
&#xD;
          -  Capability of signing an informed consent, or consent of guardian if &lt; 18 years of&#xD;
             age.&#xD;
&#xD;
          -  Ability and willingness to participate in all components of the study and receive all&#xD;
             study therapies.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Interferon-alfa.&#xD;
&#xD;
          -  Single drug prophylaxis for Mycobacterium avium or M. tuberculosis within the previous&#xD;
             4 weeks.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
        Treatment Phase:&#xD;
&#xD;
          -  Known or suspected allergy to any of the study medications. Severe hearing loss.&#xD;
&#xD;
        Maintenance Phase:&#xD;
&#xD;
          -  Severe hearing loss. Hypersensitivity to macrolides. Intolerance to ethambutol and&#xD;
             clofazimine.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Acute therapy for other opportunistic infections at time of study entry.&#xD;
&#xD;
          -  Nephrotoxic agents such as amphotericin B, intravenous vancomycin, or foscarnet during&#xD;
             the first 4 weeks of study therapy without specific exemption from one of the protocol&#xD;
             chairs. Antacids within 2 hours of ingestion of study drugs.&#xD;
&#xD;
          -  Immunomodulators (except interferon-alfa) and other antimycobacterial drugs (including&#xD;
             quinolones and aminoglycosides).&#xD;
&#xD;
          -  All experimental therapies (except ddI, ddC, and other experimental agents granted&#xD;
             &quot;Treatment IND&quot; or &quot;expanded access&quot; status) will be prohibited (specific exemptions&#xD;
             must be obtained from one of the protocol chairs).&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Known or suspected allergy to any of the study medications. Cannot take drugs orally.&#xD;
&#xD;
          -  Severe hearing loss, at the discretion of the investigator.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antimycobacterial drugs (including azithromycin, clarithromycin, rifamycins,&#xD;
             quinolones, and aminoglycosides) or immunomodulators (except interferon-alfa) within 4&#xD;
             weeks prior to entry, except single-drug prophylaxis specifically allowed.&#xD;
&#xD;
        History of unreliable drug intake.&#xD;
&#xD;
          -  Inability to cooperate in the testing procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DM Parenti</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>J Ellner</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis ConnectCare, Infectious Diseases Clinic</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NJ Med. School CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Med. Ctr., Dept. of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Center for Infectious Disease, Wendover Medical Center CRS</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington AIDS CRS</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <reference>
    <citation>Parent D, Ellner J, Hafner R, Williams M, Jacobs P, Hojczyk P. A phase II/III trial of Rifampin (RIF) Ciprofloxach (CIPRO), Clofazimine (CLOF), Ethambutol (ETH), +/- Amikacin (AK) in the treatment (RX) of Disseminated Mycobacterium avium (MA) infection in HIV-infected individuals (PTS). Natl Conf Hum Retroviruses Relat Infect (2nd). 1995 Jan 29-Feb 2:56</citation>
  </reference>
  <reference>
    <citation>Ellner JJ, Goldberger MJ, Parenti DM. Mycobacterium avium infection and AIDS: a therapeutic dilemma in rapid evolution. J Infect Dis. 1991 Jun;163(6):1326-35. doi: 10.1093/infdis/163.6.1326.</citation>
    <PMID>2037799</PMID>
  </reference>
  <reference>
    <citation>Parenti DM, Williams PL, Hafner R, Jacobs MR, Hojczyk P, Hooton TM, Barber TW, Simpson G, van der Horst C, Currier J, Powderly WG, Limjoco M, Ellner JJ. A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team. AIDS. 1998 Dec 24;12(18):2439-46. doi: 10.1097/00002030-199818000-00013.</citation>
    <PMID>9875582</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifampin</keyword>
  <keyword>Mycobacterium avium-intracellulare Infection</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Ethambutol</keyword>
  <keyword>Clofazimine</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Amikacin</keyword>
  <keyword>Azithromycin</keyword>
  <keyword>Ciprofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Amikacin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

